Studies have shown that MND patients have increased levels of Rho kinase, which is an enzyme that is involved in regulating the shape and movement of cells. Rho kinase (ROCK) has recently emerged as a possible therapeutic target in neurodegenerative conditions, including MND. This therapeutic works to inhibit ROCK, which in turn may counteract neurodegeneration and regenerate neurons. BRAVYL is an oral version of an inhibitor of Rho kinase (ROCK).
The aim of the REAL Study (Rho-kinasE for Als Study) is to assess the preliminary safety and efficacy of BRAVYL in patients with ALS. The open label study enrolled 20 patients at up to 10 sites and participants will be treated with BRAVYL for 6 months.
This trial is not currently recruiting.
For more information visit clinicaltrials.gov
